Innate Pharma (IPHYF) Net Cash Flow (2019 - 2024)
Historic Net Cash Flow for Innate Pharma (IPHYF) over the last 6 years, with Q4 2024 value amounting to -$13.8 million.
- Innate Pharma's Net Cash Flow rose 6287.93% to -$13.8 million in Q4 2024 from the same period last year, while for Jun 2025 it was -$50.9 million, marking a year-over-year increase of 2990.19%. This contributed to the annual value of -$4.0 million for FY2024, which is 7352.49% up from last year.
- Innate Pharma's Net Cash Flow amounted to -$13.8 million in Q4 2024, which was up 6287.93% from -$37.1 million recorded in Q4 2023.
- Innate Pharma's Net Cash Flow's 5-year high stood at -$1.4 million during Q2 2022, with a 5-year trough of -$79.1 million in Q4 2020.
- Its 5-year average for Net Cash Flow is -$39.2 million, with a median of -$37.1 million in 2023.
- Its Net Cash Flow has fluctuated over the past 5 years, first surged by 9632.11% in 2022, then plummeted by 87583.27% in 2023.
- Innate Pharma's Net Cash Flow (Quarter) stood at -$79.1 million in 2020, then increased by 14.09% to -$67.9 million in 2021, then soared by 68.48% to -$21.4 million in 2022, then crashed by 73.52% to -$37.1 million in 2023, then soared by 62.88% to -$13.8 million in 2024.
- Its last three reported values are -$13.8 million in Q4 2024, -$37.1 million for Q4 2023, and -$14.1 million during Q2 2023.